The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Mahmud, Sarwat ^a   Akbarzadeh, Vajiheh ^a,b   Abu Raddad, Laith J ^a,b  

^a Qatar Foundation Education City ^*  (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; GENOTYPE; HEALTH SURVEY; HEPACIVIRUS; HEPATITIS C; HUMAN; INCIDENCE; IRAN; META ANALYSIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; VIROLOGY;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; IRAN; POPULATION SURVEILLANCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 85040458567     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-18296-9     Document Type: Article

References (326)

1. Alavian, S. &Fallahian, F. Epidemiology of Hepatitis C in Iran and the World. Shiraz E Medical Journal 10, 162-172 (2009).
2. Adler, M., Goubau, P., Nevens, F. &Van Vlierberghe, H. Hepatitis C virus: the burden of the disease. Acta gastro-enterologica Belgica 65, 83-86 (2001).
3. Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet 388, 10-16 (2016).
4. WHO. Global Hepatitis Report, http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (2017).
5. The epidemiology of hepatitis C virus in the World Health Organization Eastern Mediterranean Region: Implications for strategic action. Eastern Mediterranean Hepatitis C Virus Epidemiology Synthesis Project. (in press).
6. Umar, M. et al. Hepatitis C in Pakistan: a review of available data. Hepatitis monthly 10, 205 (2010).
7. Al-Kanaani, Z., Kouyoumjian, S. P. &Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses (under preparation).
8. Qureshi, H., Bile, K., Jooma, R., Alam, S. &Afrid, H. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. Eastern Mediterranean Health Journal 16, S15 (2010).
9. Mohamoud, Y. A., Mumtaz, G. R., Riome, S., Miller, D. &Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infectious diseases 13, 288 (2013).
10. El-Zanaty, F. &Egypt, W. A. Demographic and Health Survey 2008. Cairo: Egyptian Ministry of Health, National Population Council, El-Zanaty and Associates, and ORC Macro. https://dhsprogram.com/publications/publication-fr220-dhs-final-reports. cfm (2008) (2009).
11. Brown, R. S. &Gaglio, P. J. Scope of worldwide hepatitis C problem. Liver transplantation 9, S10-S13 (2003).
12. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver April 9-13, 2014 London, United Kingdom Special Reporting on: SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in 99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study PLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation Program Professor of Medicine and Surgery Northwestern University Feinberg School of Medicine Chicago, Illinois. Gastroenterol Hepatol (N Y) 10, 1-19 (2014).
13. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Online at: http://www.who.int/ hepatitis/strategy2016-2021/ghss-hep/en/ (2016).
14. WHO. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Online at: http://www.who.int/hepatitis/ publications/hep-elimination-by-2030-brief/en/ (2016).
15. Qureshi, H., Bile, K., Jooma, R., Alam, S. &Afrid, H. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures (2010).
16. Mumtaz, G. R. et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med 11, e1001663 (2014).
17. Armstrong, G. L. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of internal medicine 144, 705-714 (2006).
18. Zafarghandi, M. B. S., Jadidi, M. &Khalili, N. Iran's Activities on Prevention, Treatment and Harm Reduction of Drug Abuse. International journal of high risk behaviors &addiction 4, e22863 (2015).
19. Razzaghi, E. M., Movaghar, A. R., Green, T. C. &Khoshnood, K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduction Journal 3, 1-13 (2006).
20. Razzaghi, E., Rahimi Movaghar, A., Hosseini, M., Madani, S. &Chatterjee, A. Rapid Situation Assessment (RSA) of drug abuse in Iran. Prevention Department, State Welfare Organization, Ministry of Health, IR of Iran and United Nations International Drug Control Program (1999).
21. Chemaitelly, H., Mahmud, S., Rahmani, A. M. &Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. International Journal of Infectious Diseases 40, 54-63 (2015).
22. Mohamoud, Y. A., Riome, S. &Abu-Raddad, L. J. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. International Journal of Infectious Diseases 46, 116-125 (2016).
23. Chemaitelly, H., Chaabna, K. &Abu-Raddad, L. J. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLOS ONE 10, e0135281 (2015).
24. Fadlalla, F. A., Mohamoud, Y. A., Mumtaz, G. R. &Abu-Raddad, L. J. The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses. PloS one 10, e0121873 (2015).
25. Chaabna, K., Kouyoumjian, S. P. &Abu-Raddad, L. J. Hepatitis C virus epidemiology in Djibouti, Somalia, Sudan, and Yemen: systematic review and meta-analysis. PloS one 11, e0149966 (2016).
26. Ayoub, H. &Abu-Raddad, L. J. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. Journal of viral hepatitis 24, 486-495 (2017).
27. Chaabna, K., Mohamoud, Y. A., Chemaitelly, H., Mumtaz, G. R. &Abu-Raddad, L. J. Protocol for a systematic review and metaanalysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. Systematic reviews 3, 1 (2014).
28. Heijnen, M., Mumtaz, G. R. &Abu-Raddad, L. J. Status of HIV and hepatitis C virus infections among prisoners in the Middle East and North Africa: review and synthesis. Journal of the International AIDS Society 19 (2016).
29. Mahmud, S. et al. Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns. Journal of Medical Virology 90, 131-141 (2018).
30. Kouyoumjian, S., Chemaitelly, H. &Abu-Raddad, L. Understanding the hepatitis C virus epidemic in Egypt: systematic reviews, meta-analyses, and meta-regression analyses (under review).
31. Higgins, J. P. &Green, S. Cochrane handbook for systematic reviews of interventions. Vol. 5 (Wiley Online Library, 2008).
32. Moher, D., Liberati, A., Tetzlaff, J. &Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151, 264-269 (2009).
33. Abu-Raddad, L. J. et al. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action. (Washington DC: The World Bank Press, 2010).
34. Abu-Raddad, L. J. et al. Epidemiology of HIV infection in the Middle East and North Africa. AidS 24, S5-S23 (2010).
35. Choo, Q.-L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
36. Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362-364 (1989).
37. Freeman, M. F. &Tukey, J. W. Transformations related to the angular and the square root. The Annals of Mathematical Statistics 21, 607-611 (1950).
38. Borenstein, M., Hedges, L. V., Higgins, J. P. T. &Rothstein, H. R. Front Matter, in Introduction to Meta-Analysis. (John Wiley &Sons, Ltd, 2009).
39. Higgins, J. P., Thompson, S. G., Deeks, J. J. &Altman, D. G. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal 327, 557 (2003).
40. Higgins, J., Thompson, S. G. &Spiegelhalter, D. J. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 172, 137-159 (2009).
41. Shannon, C. E. A mathematical theory of communication. ACM SIGMOBILE Mobile Computing and Communications Review 5, 3-55 (2001).
42. R 3.1.2: A language and environment for statistical computing (Vienna, Austria, 2014).
43. Schwarzer, G. General Package for Meta-Analysis. Version 4.1-0. Available at: http://cran.r-project.org/web/packages/meta/meta.pdf.
44. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP (2013).
45. Azarkeivan, A. et al. The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: A fourteen-year study. Transfusion 52, 1814-1818 (2012).
46. Jabbari, A., Besharat, S. &Khodabakshi, B. Hepatitis C in hemodialysis centers of golestan province, northeast of Iran (2005). Hepatitis Monthly 8, 61-65 (2008).
47. Pourmand, G. et al. Infectious complications after kidney transplantation: A single-center experience. Transplant Infectious Disease 9, 302-309 (2007).
48. Bahar, A. &Azizi, F. Insulin Resistance and β Cell Function in Patients with Chronic Hepatitis and Impaired Glucose Tolerance. Int J Endocrinol Metab 4, 125-133 (2007).
49. Dolan, K. et al. Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Subst Abuse Rehabil 3, 37-43 (2012).
50. Mohtasham Amiri, Z., Rezvani, M., Jafari Shakib, R. &Jafari Shakib, A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. Eastern Mediterranean Health Journal 13, 250-256 (2007).
51. Zamani, S. et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. International Journal of Drug Policy 18, 359-363 (2007).
52. Kheirandish, P. et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. Journal of Urban Health 86, 902-908 (2009).
53. Ataei, B., Tayeri, K., Kassaian, N., Farajzadegan, Z. &Babak, A. Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: Seroprevalence and associated factors. Hepatitis Monthly 10, 188-192 (2010).
54. Merat, S. et al. Seroprevalence of hepatitis C virus: The first population-based study from Iran. International Journal of Infectious Diseases 14, e113-e116 (2010).
55. Mir-Nasseri, M. M., Mohammadkhani, A., Tavakkoli, H., Ansari, E. &Poustchi, H. Incarceration is a major risk factor for bloodborne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon 11, 19-22 (2011).
56. Poustchi, H. et al. The impact of illicit drug use on Spontaneous Hepatitis C Clearance: Experience from a large cohort population study. PLoS ONE 6 (2011).
57. Amin-Esmaeili, M., Rahimi-Movaghar, A., Razaghi, E. M., Baghestani, A. R. &Jafari, S. Factors correlated with hepatitis C and B virus infections among injecting drug users in Tehran, IR Iran. Hepatitis Monthly 12, 23-31 (2012).
58. Kassaian, N. et al. Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran. International Journal of Preventive Medicine 3 (2012).
59. Sarkari, B. et al. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Archives of Iranian Medicine 15, 271-274 (2012).
60. Abedian, S., Firoozi, M. &Malekzadeh, R. Etiology of hepatocellular carcinoma in IRAN: Single center experience in a large referral center, 2000-2011. Journal of Gastroenterology and Hepatology 28, 607 (2013).
61. Alipour, A. et al. High prevalence of HCV coinfection in HIV-infected individuals in Shiraz, Islamic Republic of Iran. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 19, 975-981 (2013).
62. Mir-Nasseri, S. et al. HCV in intravenous drug users. Govaresh 10, 80-86 (2005).
63. Seyed Alinaghi, S. et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection-drug users in Iran. Clinical Microbiology and Infection 16, S334-S335 (2010).
64. Zamani, S. et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peerdriven sampling in Iran. International Journal of Drug Policy 21, 493-500 (2010).
65. Nokhodian, Z. et al. Seroprevalence and risk factors of hepatitis C virus among juveniles in correctional center in Isfahan, Iran. International Journal of Preventive Medicine 3 (2012).
66. Nokhodian, Z. et al. Prevalence and risk factors of HIV, syphilis, hepatitis B and C among female prisoners in Isfahan, Iran. Hepatitis Monthly 12, 92-97 (2012).
67. Alipour, A., Rezaianzadeh, A., Hasanzadeh, J., Rajaeefard, A. &Davarpanah, M. A. Sexual transmission of hepatitis C virus between HIV infected subjects and their main heterosexual partners. Hepatitis Monthly 13 (2013).
68. Mehrjerdi, Z. A., Abarashi, Z., Noroozi, A., Arshad, L. &Zarghami, M. Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: The first report from Iran. International Journal of STD and AIDS 25, 420-427 (2014).
69. Salehi, A., Naghshvarian, M., Marzban, M. &Lankarani, K. B. Prevalence of HIV, HCV, and High-Risk behaviors for substance users in drop in centers in southern Iran. Journal of Addiction Medicine 9, 181-187 (2015).
70. Zakizad, M. et al. Seroprevalence of hepatitis C infection and associated risk factors among addicted prisoners in Sari-Iran. Pakistan journal of biological sciences: PJBS 12, 1012-1018 (2009).
71. Hosseini Asl, S. K., Avijgan, M. &Mohamadnejad, M. High prevalence of HBV, HCV, and HIV infections in gypsy population residing Shahr-e-Kord. Archives of Iranian Medicine 7, 20-22 (2004).
72. Azizi, A., Amirian, F. &Amirian, M. Prevalence and Associated Factors of Hepatitis C in Self-introduced Substance Abusers. Hayat 17, 55-61 (2011).
73. Mansour-Ghanaei, F. et al. Seroprevalence of hepatitis B and C among residents of Guilan Nursing Home. Hepat Mon 7, 139-1141 (2007).
74. Samimi-Rad, K., Hosseini, M. &Shahbaz, B. Hepatitis C virus infection and hcv genotypes of hemodialysis patients. Iranian Journal of Public Health 37, 146-152 (2008).
75. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 17, 107-115 (2011).
76. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. &Wiersma, S. T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013).
77. Cornberg, M. et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 31, 30-60 (2011).
78. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. &Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of hepatology 61, S45-S57 (2014).
79. Mumtaz, G. R., Awad, S. F., Faizzadeh, A., Weiss, H. A. &LJ, A.-R. HIV incidence among people who inject drugs in the Middle East and North Africa: mathematical modeling analysis (under review).
80. United Nations Office on Drugs and Crime. World drug report, 2015. https://www.unodc.org/documents/wdr2015/WorldDrug Report2015.pdf (2015).
81. Calabrese, J. Iran's War on Drugs: Holding the line. The Middle East Institute, Policy Brief 3, 1-18 (2007).
82. Alter, M. J. Epidemiology of hepatitis C virus infection. World Journal of gastroenterology 13, 2436 (2007).
83. Shepard, C. W., Finelli, L. &Alter, M. J. Global epidemiology of hepatitis C virus infection. The Lancet infectious diseases 5, 558-567 (2005).
84. Lansky, A. et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 9, e97596 (2014).
85. Armstrong, G. L. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144, 705-714 (2006).
86. Denniston, M. M. et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160, 293-300 (2014).
87. Zobeiri, M., Adibi, P. &Alavian, S. M. Intravenous drug use and hepatitis C virus in iran. Hepatitis monthly 12, 9-10 (2012).
88. Harm Reduction International. The global state of harm reduction 2012: Towards an integrated response. https://www.hri.global/ global-state-of-harm-reduction-2012 (2012).
89. Nissaramanesh, B., Trace, M. &Roberts, M. The rise of harm reduction in the Islamic Republic of Iran. Beckley Foundation Drug Policy Programme, Briefing Paper 8 (2005).
90. Zafarghandi, M. B. S., Jadidi, M. &Khalili, N. Iran's Activities on Prevention, Treatment and Harm Reduction of Drug Abuse. International Journal of High Risk Behaviors and Addiction 4 (2015).
91. Alavian, S.-M., Adibi, P. &Zali, M.-R. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med 8, 84-90 (2005).
92. Alavian, S., Kafaee, J., Yektaparast, B., Hajarizadeh, B. &Doroudi, T. The efficacy of blood donor screening in reducing the incidence of hepatitis C virus infection among thalassemic patients in Iran. Transfusion Today 53, 3-4 (2002).
93. Azarkeivan, A. et al. Evaluation of new cases of HCV infection in thalassaemia patients for source of infection. Asian journal of transfusion science 5, 132 (2011).
94. Alavian, S. M., Bagheri-Lankarani, K., Mahdavi-Mazdeh, M. &Nourozi, S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodialysis international 12, 378-382 (2008).
95. Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87 (2015).
96. Taherkhani, R. &Farshadpour, F. Epidemiology of hepatitis C virus in Iran. World Journal of Gastroenterology 21, 10790-10810 (2015).
97. Sefidi, F. J. et al. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepatitis Monthly 13, e7991 (2013).
98. Sefidi, F. J. et al. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepatitis monthly 13 (2013).
99. Cuadros, D. F., Branscum, A. J., Miller, F. D. &Abu-Raddad, L. J. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology 60, 1150-1159 (2014).
100. Miller, F. D. &Abu-Raddad, L. J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proceedings of the National Academy of Sciences 107, 14757-14762 (2010).
101. Chemaitelly, H., Abu-Raddad, L. J. &Miller, F. D. An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. PloS one 8, e69803 (2013).
102. Benova, L., Awad, S. F., Miller, F. D. &Abu-Raddad, L. J. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology 61, 834-842 (2015).
103. Guerra, J., Garenne, M., Mohamed, M. &Fontanet, A. HCV burden of infection in Egypt: results from a nationwide survey. Journal of viral hepatitis 19, 560-567 (2012).
104. Benova, L., Awad, S. F. &Abu-Raddad, L. J. Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts. Journal of Viral Hepatitis 00, 1-7 (2017).
105. Abu-Raddad, L. J. et al. Policy Notes. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: Time for Strategic Action. Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication. (The World Bank Press, 2010).
106. World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings. http://apps.who.int/iris/handle/10665/250144 (2016).
107. Organization, W. H. Making all injections safe. Geneva, Switzerland: WHO (2015).
108. Afzali, H., Taghavi, A. &Gholamreza, G. Seroepidemiology of hepatitis B and C in blood donors in Kashan, 1996-1999 [Persian]. Feyz 6, 43-50 (2002).
109. Aghajaanipour, K. &Zandieh, T. Seroepidemiology of hepatitis B, C and HIV in healthy blood donors in Babol city center in 2002 [Persian]. Blood Quarterly Journal 2, 339-341 (2006).
110. Alavi, S. et al. Torque teno virus and hepatitis C virus co-infection in Iranian pediatric thalassemia patients. Turkish journal of haematology: official journal of Turkish Society of Haematology 29, 156-161 (2012).
111. Alavian, S. M., Gholami, B. &Masarrat, S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. Journal of Gastroenterology and Hepatology 17, 1092-1097 (2002).
112. Alavian, S. M. et al. Anti-hepatitis e antibody in hemodialysis patients in Isfahan, Iran: Prevalence and risk factors. Hepatitis Monthly 15, e23633 (2015).
113. Amini, S., Mahmoodabadi, S. A., Lamian, S., Joulaie, M. &Farahani, M. M. Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health 34, 41-46 (2005).
114. Ansar, M. M. &Kooloobandi, A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. Journal of Viral Hepatitis 9, 390-392 (2002).
115. Ansari-Moghaddam, A. et al. Seroprevalence of Hepatitis B Surface Antigen and Anti Hepatitis C Antibody in Zahedan City, Iran: A Population-Based Study. Hepatitis Monthly 12, 1-7 (2012).
116. Ardebili, M., Fattahi, M. R., Khademolhosseini, F., Shirazi, Z. H. &Doust, F. M. Hepatitis C infection in a rural population in southern Iran: A report from kavar cohort study. Hepatology International 6(1), 154 (2012).
117. Arfaee, R. et al. The prevalence of hepatitis B and C virus infection in war veterans of the 27th Islamic Revolutionary Guard Corps [Persian]. Military Medicine Magazine 4, 6-9 (2002).
118. Assarehzadegan, M. A., Shakerinejad, G., Amini, A. &Rezaee, S. A. R. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, Southwest Iran. International Journal of Infectious Diseases 12, 387-390 (2008).
119. Sayad, B. et al. Seroepidemiology of hepatitis C in Kermanshah (West of Iran, 2006). Hepatitis Monthly 8, 141-146 (2008).
120. Barhaghtalab, M. Y., Saboori, S., Damiri, M. &Ekrahi, M. Prevalence of Viral Markers for Hepatitis B and C in Healthy Volunteer Blood Donors in Fasa Region, South Iran. International Journal of Infectious Diseases 12, e87 (2008).
121. Bozorgi, S. H. et al. Risk factors of viral hepatitis: yet to explore. Transfus Apher Sci 47, 145-149 (2012).
122. Chamani, L. et al. Seroepidemiologic study of CMV, toxoplasma and hepatitis B and C in clients of Avicenna Infertility Clinic. Iran J Infect Dis Trop Med 11, 59-63 (2007).
123. Delavari, M. &Tabatabaei, S. Frequency of hepatitis C and its related factors in blood donors in Kerman in 2003. Annals of Military and Health Sciences Research 2, 323-358 (2004).
124. Doosti, A., Arnini-Bavil-Olyaee, S., Tajbakhsh, E., Adeli, A. &Mahboudi, F. Prevalence of viral hepatitis and molecular analysis of HBV among voluntary blood donors in west Iran. New Microbiologica 32, 193-198 (2009).
125. Emamghorashi, F., Fathi, G. &Mohtashami, A. Evaluation of demographic characteristics and hepatitis B, C and HIV prevalence among blood donors in Jahrom. SJIBTO 2, 373-378 (2006).
126. Fallahian, F. &Najafi, A. Epidemiology of hepatitis C in the Middle East. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 22, 1-9 (2011).
127. Esfandiarpour, I., Zandi, S., Rahnama, Z. &Dervish, D. Prevalence of anti-HCV-Ab (C) antibacterial antibody in psoriasis patients in Kerman [Persian]. Scientific Journal of Hamadan University of Medical Sciences &Health services 12, 5-9 (2005).
128. Esmaeili, M., Mostafazadeh, A., Sharbatdarn, M., Hajiahmadi, M. &Alijanpoor, M. Hepatitis C in blood products receivers. Iranian Journal of Pediatrics 14, 15-20 (2004).
129. Esmaieli, H., Hajiani, G., Mankhian, A. &Poumehdi Broujeni, M. Seroepidemiological survey of hepatitis B, C, HIV and syphilis among blood donors in Bushehr-Iran. ISMJ 11, 183-190 (2009).
130. Farajzadeh, S., Shakibi, M. R., Moghaddam, S. D. &Rahnama, Z. Behcet disease: clinical spectrum and association with hepatitis B and C viruses. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 11, 68-72 (2005).
131. Farshadpour, F., Makvandi, M., Samarbafzadeh, A. R. &Jalalifar, M. A. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. Indian Journal of Medical Microbiology 28, 54-56 (2010).
132. Farshadpour, F. et al. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study. PLoS One 11, e0157615 (2016).
133. Gachkar, L. et al. Frequency of antibodies to hepatitis E virus among male blood donors in Tabriz. The Scientific Journal of Iranian Blood Transfusion Organization 2, 157-162 (2005).
134. Gerayli, S. et al. The association between oral lichen planus and hepatitis C virus infection; a report from northeast of Iran. Jundishapur Journal of Microbiology 8, e16741 (2015).
135. Ghaderi, R. &Makhmalbaf, Z. The Relationship between Lichen Planus and Hepatitis C in Birjand, Iran. Shiraz E-Med J 8, 72-79 (2007).
136. Ghadir, M. et al. Hepatitis C in Golestan Province-Iran. Govaresh 11, 158-162 (2006).
137. Ghafouri, M. &Ameli, M. Comparing prevalence of transfusion transmitted viral infections in various population groups of South Khorasan. The Scientific Journal of Iranian Blood Transfusion Organization 7, 242-268 (2011).
138. Ghavanini, A. A. &Sabri, M. R. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-ihhiyah li-sharq al-mutawassi 6, 1114-1116 (2000).
139. Ghezeldasht, S. A. et al. Oncogenic virus infections in the general population and end-stage renal disease patients with special emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran. Jundishapur Journal of Microbiology 8, e14920 (2015).
140. Habibzadeh, S., Davarnia, B., Bagherzadeh, J. &Kholgh, G. Epidemiological evaluation of transfusion transmitted diseases in Ardabil in Tasoua and Ashoura 1381 (2003). The Scientific Journal of Iranian Blood Transfusion Organization 1, 55-60 (2005).
141. Hajiani, E., Hashemi, S. J., Masjedi-zade, A. &Cheraghi, M. Risk of Hepatitis C Virus transmission Following Upper Gastrointestinal Endoscopy. Yafteh 8, 47-54 (2006).
142. Hajiani, E., Masjedizadeh, R., Hashemi, J., Azmi, M. &Rajabi, T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. World J Gastroenterol 12, 7025-7028 (2006).
143. Sharify Heydarabad, H., Farid Soltany, F. &Montazam, S. H. Seroepidemiology of sti viruses in pregnant women: A retrospective study 2010-2011. Journal of Sexual Medicine 9, 395 (2012).
144. Khedmat, H. et al. Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in Iranian blood donors from 2003 to 2005. Hepatitis Monthly 9, 24-28 (2009).
145. Hosseini, I. et al. Survey on the status of hepatitis C, B, AIDS and syphillis in blood donors in Bushehr Province in 2005 [Persian]. Infectious and Tropical Diseases of Iran 12, 85-88 (2007).
146. Jadali, Z., Esfahanian, F., Farhoud, D., Alavian, S. &Soltan Dallal, M. Hashimoto's Thyroiditis and Its Association with Hepatitis C Virus Infection. Int J Endocrinol Metab 3, 116-120 (2005).
147. Jadali, Z., Esfahanian, F., Eslami, M. B. &Sanati, M. H. Serum Antibodies against Hepatitis C Virus in Iranian Patients with Graves' Disease. Iranian journal of allergy, asthma, and immunology 4, 91-94 (2005).
148. Jamali, R. et al. Persistent alanine aminotransferase elevation among the general Iranian population: Prevalence and causes. World Journal of Gastroenterology 14, 2867-2871 (2008).
149. Amini Kafi-Abad, S., Rezvan, H., Abolghasemi, H. &Talebian, A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion 49, 2214-2220 (2009).
150. Mowla, K. &Hajiani, E. Prevalence of Hepatitis C Virus Infection in Patients with Systemic Lupus Erythematosus: A Case-Control Study. Hepat Mon 8, 41-44 (2008).
151. Karimi, A. &Hoseini, S. M. Seroprevalence of hepatitis B and C virus and HIV markers among blood donors from Shahre-Kord, Iran (2004-2006). Kuwait Medical Journal 40, 285-287 (2008).
152. Kasraian, L. &Tavassoli, A. Prevalence of hepatitis C and its risk factors in blood donors at Shiraz transfusion center. Koomesh 10, 7-12 (2008).
153. Kasraian, L. National disasters in iran and blood donation: Bam earthquake experience. Iranian Red Crescent Medical Journal 12, 316-318 (2010).
154. Kasraian, L. &Torab Jahromi, S. A. Prevalence of major transfusion-transmissible viral infections in blood donors attending Fars Blood Transfusion Center, Shiraz, southern Iran: 2002-05. Iranian Journal of Medical Sciences 32, 114-117 (2007).
155. Kavoosi, H., Ebrahimi, A., Rezaei, M. &Jahani, M. Association of Lichen Planus with Hepatitis B and C. Journal of Kermanshah University of Medical Sciences 11 (2008).
156. Kazemi Nejad, V., Azar Housh, R. &Molana, A. &GR, D. Frequency of Hepatitis B virus, Hepatitis C virus and human immunodeficiency virus in blood donors and patients in Gorgan Blood Transfusion Organization in 2003 [Persian]. Journal of Gorgan University of Medical Sciences 15, 84-86 (2005).
157. Keshvari, M., Sharafi, H., Alavian, S. M., Mehrabadi, H. &Zolfaghari, S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. Transfusion and Apheresis Science 53, 38-47 (2015).
158. Khedmat, H. et al. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. Pakistan Journal of Biological Sciences 10, 4461-4466 (2007).
159. Aghamohamad, A., Montazeri, M. &Akbari, M. Prevalence of hepatitis B and hepatitis C in blood donors at Semnan province from 2008 to 2011. Koomesh 15, Pe162-Pe167, En123 (2014).
160. Kordi, R., Neal, K., Pourfathollah, A. A., Mansournia, M. A. &Wallace, W. A. Risk of hepatitis B and C infections in Tehranian wrestlers. Journal of athletic training 46, 445-450 (2011).
161. Mahmoodian-Shooshtari, M. &Pourfathollah, A. An overview analysis of blood donation in the Islamic Republic of Iran. Archives of Iranian Medicine 9, 200-203 (2006).
162. Maneshi, H. O., Zare, S., Karimi, M. &Hajiani, G. R. HBV and HCV viral markers seroperevalence in first-time healthy blood donors refered to transfusion centers of bushehr province, South of Iran (April 2004 to March 2008). Retrovirology 7, P151 (2010).
163. Mansour-Ghanaei, F. et al. Prevalence of hepatitis B surface antigen and hepatitis C virus antibody and their risk factors among Guilan's volunteer blood donors (1998-2003). Hepat Mon 7, 239-241 (2007).
164. Masaeli, Z., Jaberi, M. &Magsudlu, M. A comparison of seroprevalence of blood-borne infections among regular, sporadic, and first-time blood donors in Isfahan. The Scientific Journal of Iranian Blood Transfusion Organization 2, 301-307 (2006).
165. Metanat, M. et al. Prevalence of hepatitis C among diabetes mellitus patients in Zahedan. Zahedan Journal of Research in Medical Sciences 8, 179-186 (2006).
166. Moezzi, M., Imani, R., Karimi, A. &Pourheidar, B. Hepatitis C seroprevalence and risk factors in adult population of Chaharmahal and Bakhtiari province of Iran in 2013. Journal of Clinical and Diagnostic Research 9, LC13-LC17 (2015).
167. Mogaddam, M. R. &Anamzade, F. Survey of relationship between hepatitis C and lichen planus among dermatology outpatients of Imam Hospital of Ardabil city. Journal of Pakistan Association of Dermatologists 20, 19-22 (2010).
168. Mohammadali, F. &Pourfathollah, A. Association of ABO and Rh Blood Groups to Blood-Borne Infections among Blood Donors in Tehran-Iran. Iranian journal of public health 43, 981 (2014).
169. Mohebbi, S. R. et al. Hepatitis C and hepatitis B virus infection: Epidemiology and risk factors in a large cohort of pregnant women in Lorestan, West of Iran. Hepatitis Monthly 11, 736-739 (2011).
170. Moniri, R., Mosayebii, Z. &Mossavi, G. Seroprevalence of cytomegalovirus, hepatitis B, hepatitis C and human immunodeficiency virus antibodies among volunteer blood donors. Iranian Journal of Public Health 33, 38-42 (2004).
171. Moradi, A. et al. Seroepidemiology of Rubella, Measles, HBV, HCV and B19 Virus Within Women in Child Bearing Ages (Saravan City of Sistan and Bloochastan Province). Research Journal of Microbiology 2 (2007).
172. Motlagh, M. E., Makvandi, M. &M, J. Prevalence of anti-HCV among pregnant women. The Journal of Qazvin University of Medical Science 5, 59-63 (2001).
173. Beladi Mousavi, S. S., Hayati, F. &Ghorbani, A. Seroprevalence of cytomegalovirus antibody in renal transplant recipients and donors in Khuzestan Province, Iran. Shiraz E Medical Journal 11, 203-208 (2010).
174. Mousavi, S. S. B. &Hayati, F. Do we need to screen our patients for EBVIgGantibody before kidney transplantation? Nephro-Urology Monthly 3, 122-124 (2011).
175. Pourshams, A. et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. Journal of Gastroenterology and Hepatology 20, 229-233 (2005).
176. Rahbar, A. R., Rooholamini, S. &Khoshnood, K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy 15, 151-155 (2004).
177. Rahnama, Z., Esfandiarpour, I. &Farajzadeh, S. The relationship between lichen planus and hepatitis C in dermatology outpatients in Kerman, Iran. International Journal of Dermatology 44, 746-748 (2005).
178. Razjou, F., Maghsudlu, M., Nasizadeh, S. &Zadsar, M. The impact of donor selection on blood safety in Iran. Transfusion and Apheresis Science 47, 13-16 (2012).
179. Rezaie, M. &Khaleghian, A. Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan Province (Iran) from 2011 to 2015. [Persian]. Koomesh 17, 501-508 (2016).
180. Rezazadeh, M. et al. Prevalence of human immunodeficiency, hepatitis B and hepatitis C viruses in the first time, repeat and regular donors in blood transfusion center, Hamadan, 2004-2005. Iranian Journal of Infectious Diseases and Tropical Medicine 11, 55-60 (2006).
181. Nikbakht, R., Saadati, N. &Firoozian, F. Prevalence of HBsAG, HCV and HIV antibodies among infertile couples in Ahvaz, South-West Iran. Jundishapur Journal of Microbiology 5, 393-397 (2012).
182. Salehi, H., Salehi, M., Ardestani, M. K., Khorvash, F. &Zadeh, K. M. Comparing the Blood Safety on the Blood Donors within the Religious Ceremonies and Routine Conditions. Journal of Isfahan Medical School 28 (2011).
183. Samadi, M. et al. The comparison of the prevalence rates of HBV, HCV, and HIV in blood donors having deferred for high risk behaviors. Scientific Journal of Iranian Blood Transfusion Organization 10, 347-352 (2014).
184. Seyed-Askari, S. M., Beigzadeh, A. &Mohammadpoor-Ravari, M. The prevalence of transfusion transmitted infections among blood donors in Kerman, Iran. [Persian]. Journal of Kerman University of Medical Sciences 22, 669-676 (2015).
185. Shaheli, M., Yaghobi, R., Rezaeian, A., Saadi, M. I. &Ramzi, M. Study of the associations between TT Virus single and mixed infections with leukemia. Jundishapur Journal of Microbiology 8, e18212 (2015).
186. Javadzadeh Shahshahani, H., Vaziri, M. &Mansouri, F. Seven Years Trends in Prevalence of Transfusion-Transmissible Viral Infections in Yazd blood Transfusion Organization. Iran J Ped Hematol Oncol 3, 119-124 (2013).
187. Shakeri, M. T. et al. The prevalence of hepatitis C virus in Mashhad, Iran: A population-based study. Hepatitis Monthly 13 (2013).
188. Shamsdin, S. A. &Fattahi, M. R. &Amirzadeh fard, S. The prevalence of hepatitis C infection in general population in Shiraz, southern Iran. International Journal of Infectious Diseases 16, e110 (2012).
189. Sofian, M. et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. International Journal of Infectious Diseases 14, e308-e310 (2010).
190. Sohrabpour, A. et al. Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. Middle East J Dig Dis 2, 14-19 (2010).
191. Tahereh Vahid, M., Seyed-Moayed Alavian, M., Ali Kabir, M. &Jafar Kafaee, M. Hepatitis B Prevalence and Risk Factors in Blood Donors in Ghazvin, IR. IranI. Hepatitis Monthly 5, 117-122 (2005).
192. Taheri Azbarmi, Z. et al. Transfusion transmitted disease in Rasht blood donors. The Scientific Journal of Iranian Blood Transfusion Organization 4, 337-343 (2008).
193. Tajbakhsh, E., Yaghobi, R. &Vahedi, A. R. A serological survey on hepatitis C virus Antibody in blood donors with an ELISA method. Tehran University Medical Journal 65, 69-73 (2007).
194. A. Tanomand, H. M. A. M. K. Seroepidemiology of Hepatitis C Antibody Between Rural and Urban People: A Retrospective Study in June to December of 2005 in Malekan City, Iran. Research Journal of Biological Sciences 2, 561-563 (2007).
195. Vahidi, A., Taheri, A. &Nikian, Y. Prevalence of Hepatitis C among Thalassemic patients referring to Kerman university of medical sciences hospital No. 1 in 1996. Journal of Kerman University of Medical Sciences 7, 110-114 (2000).
196. Yazdani, M. &Shakeri, S. Vertical transmission of hepatitis C from pregnant-mothers to their. Bimonthly Journal of Hormozgan University of Medical Sciences 10, 145-149 (2006).
197. Zamani, F. et al. Prevalence and risk factors of hepatitis C virus infection in Amol city, north of Iran: A population-Based study (2008-2011). Hepatitis Monthly 13 (2013).
198. Sorouri Zanjani, R., Mazloomzadeh, S., Koocheki, A. &Noori, M. Prevalence of Hepatitis B, C and HIV Infection in Blood Donors in Zanjan, 2005-2006. Preventive Care In Nursing &Midwifery Journal 3, 56-63 (2013).
199. Abdollahi, A. et al. Seroprevalence of Human Immunodificiency Virus (HIV) and Hepatitis C Infection in Hemophilic Patients in Iran. Iranian Journal of Pathology 3, 119-124 (2008).
200. Aghakhani, A., Ramezani, A., Mohraz, M., Banifazl, M. &Eslamifar, A. Significance of hepatitis B core antibody as the only marker of hepatitis B virus infection in high risk patients. Iranian Journal of Pathology 4, 80-84 (2009).
201. Akbari, A., Imanieh, M., Karimi, M. &Tabatabaee, H. Hepatitis C virus antibody positive cases in multitransfused thalassaemic patients in south of Iran. Hepatology International 5, 223 (2011).
202. Alvai, S., Arzanian, M., Hatami, K. &Shirani, A. Frequency of hepatitis C in thalassemic patients and its association with liver enzyme, MOfid Hospital, Iran, 2002. Pejouhesh 29, 213-217 (2005).
203. Alavi, S. M. &Etemadi, A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences 23, 510-513 (2007).
204. Alavi, S. M. &Alavi, L. Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001-2006). Journal of Infection and Public Health 2, 47-51 (2009).
205. Alavia, S. et al. The prevalence of Hepatitis B and C among thalassemia major patients in Ghazvin. Kowsar Medical Journal 7, 319-326 (2003).
206. Alavian, S., Ardeshiri, A. &Hajarizadeh, B. Prevalence of HCV, HBV and HIV infections among hemophiliacs. J tongji Med Univ 14, 178-180 (1994).
207. Alipour, A., Haghdoost, A. A., Sajadi, L. &Zolala, F. HIV prevalence and related risk behaviours among female partners of male injecting drugs users in Iran: Results of a bio-behavioural survey, 2010. Sexually Transmitted Infections 89, iii41-iii44 (2013).
208. Alizadeh, A. H. M., Alavian, S. M., Jafari, K. &Yazdi, N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World Journal of Gastroenterology 11, 4085-4089 (2005).
209. Mohammad Alizadeh, A. et al. Frequencies of hepatitis B and C infections in hemophiliacs. Research in Medicine 30, 119-123 (2006).
210. Ameli, M., Besharati, S., Nemati, K. &Zamani, F. Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Medical Journal 29, 1611-1615 (2008).
211. Amiri, Z. M., Shakib, A. J. &Toorchi, M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. Eastern Mediterranean Health Journal 11, 372-376 (2005).
212. Ansari, H., Kamani, H. &Arbabi Sarjo, A. Prevalence of hepatitis C and related factors among beta-thalassemia major patients in Southern Iran in 2005-2006. Journal of Medical Sciences 7, 997-1002 (2007).
213. Asl, R. T. et al. Outcome assessment of a triangular clinic as a harm reduction intervention in Rajaee-Shahr Prison, Iran. Harm Reduction Journal 10 (2013).
214. Assarehzadegan, M. A., Boroujerdnia, M. G. &Zandian, K. Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in Ahvaz, Southwest Iran. Iranian Red Crescent Medical Journal 14, 3 (2012).
215. Ataei, B. et al. Seroepidemiology of hepatitis C in cases with history of intravenous drug use in Isfahan province, Iran. Clinical Microbiology and Infection 16, S314 (2010).
216. Ataei, B. et al. Hepatitis c in intravenous drug users: seroprevalence and risk factors. J Isfahan Med Sch 28, 1537-1545 (2011).
217. Ataei, B. et al. Hepatitis C Screening in Intravenuos Drug Users in Golpayegan, Isfahan through Community Announcement: Pilot Study. Journal of Isfahan Medical School 28 (2011).
218. Ataei, B. et al. Prevalence of anti HCV infection in patients with beta-thalassemia in Isfahan-Iran. International Journal of Preventive Medicine 3 (2012).
219. Azarkeivan, A. et al. Trace back of thalassemic patients with positive HCV markers to their donors in Adult Thalassemia Center. Sci J Blood Transfus Organ 7, 156-161 (2010).
220. Azarkeivan, A. et al. Evaluation of clinical conditions of thalassemic patients having referred to Adult Thalassemia Center, Tehran. Sci J Iran Blood Transfus Organ 8, 32-41 (2011).
221. Babamahmoodi, F., Gorji, M. A. H., Nasehi, M. M. &Delavarian, L. The prevalence rate of hepatitis B and hepatitis C co-infection in HIV positive patients in Mazandaran province, Iran. Medicinski Glasnik 9, 299-303 (2012).
222. Basirat Nia, M. &Asl, S. Determining the prevalence of hepatitis C in patients with thalassemia in Shahrekord, 1998 [Persian]. Research in Medicine 26, 9-13 (2002).
223. Boroujerdnia, M. G., Zadegan, M. A. A., Zandian, K. M. &Rodan, M. H. Prevalence of hepatitis-C virus (HCV) among thalassemia patients in Khuzestan province, southwest Iran. Pakistan Journal of Medical Sciences 25, 113-117 (2009).
224. Bozorghi, S. et al. Assessment of prevalence and risk factors of hepatitis C virus infection in haemodialysis patients in Ghazvin. The Scientific Journal of Iranian Blood Transfusion Organization 2, 331-337 (2006).
225. Bozorghi, S. et al. The prevalence and risk factors of hepatitis C virus infection among thalassemic patients of Qazvin (2005). J Qazvin Univ Med Sci 11, 54-59 (2008).
226. Broumand, B. et al. Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in tehran: preliminary report from "the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients" project. Saudi J Kidney Dis Transpl 13, 467-472 (2002).
227. Company, F. &Rezaei, N. Prevalence of hepatitis C and its relationship with glucose and diabetes mellitus in patients with major beta thalassemia [Persian]. Scientific Journal of Kurdistan University of Medical Sciences 12, 45-52 (2007).
228. Dadgaran, S. Prevalence and risk factors of hepatitis C virus among hemodialysis patients. Journal of Guilan University of Medical Sciences 14, 76-86 (2005).
229. Dadmanesh, M. et al. Evaluation of prevalence and risk factors of hepatitis G virus infection among hemodialysis patients referred to Iranian Army Hospitals in Tehran during 2012-2013. Hepatitis monthly 15, e18322 (2015).
230. Davarpanah, M. A. et al. Hepatitis C Virus Infection in HIV Positive Attendees of Shiraz Behavioral Diseases Consultation Center in Southern Iran. Indian J Community Med 38, 86-91 (2013).
231. Davoodian, P., Dadvand, H., Mahoori, K., Amoozandeh, A. &Salavati, A. Prevalence of selected sexually and blood-borne infections in injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Brazilian Journal of Infectious Diseases 13, 356-358 (2009).
232. Eghbalian, F &AR, M. Study of prevalence of posttransfusion infections in Hamadan Thalassemic children. Scientific Journal of Hamedan University of Medical Sciences 17 (2000).
233. Esfahani, H. &Bazmamoun, H. The prevalence of blood-borne viral infection (HBV, HCV, HIV) among hemophilia patients in Hamedan province of Iran. Iranian Journal of Blood and Cancer 6, 209-211 (2014).
234. Eskandarieh, S. et al. Descriptive Aspects of Injection Drug Users in Iran's National Harm Reduction Program by Methadone Maintenance Treatment. Iran J Public Health 42, 588-593 (2013).
235. Eslamifar, A. et al. Hepatitis G virus exposure in dialysis patients. International Urology and Nephrology 39, 1257-1263 (2007).
236. Etminani-Esfahani, M. et al. Serum vitamin D concentration and potential risk factors for its deficiency in HIV positive individuals. Current HIV Research 10, 165-170 (2012).
237. Faramarzi, H., Amini Lari, M., Marzban, M. &Shams, M. Hypogonadism and associated factors among men with HIV infection in Shiraz, Southern Iran. Sexually Transmitted Infections 89 (2013).
238. Faranoush, M. et al. Prevalence of hepatitis C resulted from blood transfusion in major thalassemia patients in Semnan, Damghan and Garmsar (2002). Medical Journal of Hormozgan University 10, 77-82 (2006).
239. Farhoudi, B., SeyedAlinaghi, S., Mohraz, M., Hosseini, M. &Farnia, M. Tuberculosis, hepatitis C and hepatitis B co-infections in patients with HIV in the Great Tehran Prison, Iran. Asian Pacific Journal of Tropical Disease 6, 82-83 (2016).
240. Ghaderi, A. &Habib-Agahi, M. High prevalence of anti-HCV and HTLV-1 antibodies in thalassemia major patients of southern Iran. Irn J Med Sci 21, 2 (1996).
241. Ghadir, M., Movahhed, M., Movahhed, A., Movahhed, T. &Heidari, A. Effect of hepatitis C and B infections on anemia in hemodialysis patients. Journal of Medical Council of Islamic Republic of Iran 27, Pe9-Pe15, En155 (2009).
242. Ghafourian-Boroujerdnia, M., Asarehzadegan, M. &Zandian, K. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus (HIV) among thalassemia patients refer to Ahwaz Shapha hospital (1999-2004). Jundishapur Journal of Microbiology 5, 523-529 (2006).
243. Ghane, M., Eghbali, M., Nejad, H. R., Saeb, K. &Farahani, M. Distribution of hepatitis C virus genotypes amongst the betathalassemia patients in north of Iran. Pakistan Journal of Biological Sciences 15, 748-753 (2012).
244. Haghazali, S. et al. Occult HBV infection in hemodialysis patients in Qazvin. Razi Journal of Medical Sciences 18, 8-15 (2011).
245. Hamissi, J. &Hamissi, H. Occurrence of hepatitis B and C infection among hemodialyzed patients with chronic renal failure in Qazvin, Iran: A preliminary study. International Journal of Collaborative Research on Internal Medicine &Public Health 3, 89-96 (2011).
246. Hariri, M., Akbari, N., Yavari, F., Javadi, E. &Javer, S. In Vox Sanguinis. 268-268 (Wiley-Blackwell).
247. Honarvar, B. et al. Blood-borne hepatitis in opiate users in Iran: A poor outlook and urgent need to change nationwide screening policy. PLoS ONE 8 (2013).
248. Imani, R., Karimi, A., Rouzbahani, R. &Rouzbahani, A. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. Eastern Mediterranean Health Journal 14, 1136-1141 (2008).
249. Ismail, H. et al. Investigation of intravenous drug users and determining the rate of HIV and hepatitis virus in Loghman Hakim hospital [Persian]. Iranian Journal of Surgery 13, 89-94 (2005).
250. Joukar, F., Besharati, S., Mirpour, H. &Mansour-Ghanaei, F. Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. Hepat Mon 11, 178-181 (2011).
251. Kaffashian, A. et al. The experience of hepatitis C screening among prison inmates with drug injection history. Journal of Isfahan Medical School 28 (2011).
252. Kalantari, H., Mirzabaghi, A., Akbari, M. &Shahshahan, Z. Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients in Iran. Iranian Journal of Clinical Infectious Diseases 6, 82-84 (2011).
253. Kalantari, H., Ebadi, S., Yaran, M., Maracy, M. R. &Shahshahan, Z. Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in Isfahan, Iran. Adv Biomed Res 3, 73 (2014).
254. Karimi, M. &Ghavanini, A. A. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. Journal of Paediatrics and Child Health 37, 564-566 (2001).
255. Karimi, M. &Ghavanini, A. A. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia 31, 251-255 (2001).
256. Karimi, M., Ardeshiri, R. &Yarmohammadi, H. Inherited coagulation disorders in southern Iran. Haemophilia 8, 740-744 (2002).
257. Kashef, S. et al. Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. International Journal of Laboratory Hematology 30, 11-16 (2008).
258. Kassaian, N. et al. Hepatitis C in patients with multi blood transfusion in Isfahan, Iran. Hepatology International 5(1), 226 (2011).
259. Keramat, F., Eini, P. &Majzoobi, M. M. Seroprevalence of HIV, HBV and HCV in persons referred to hamadan behavioral counseling center, west of Iran. Iranian Red Crescent Medical Journal 13, 42-46 (2011).
260. Keshvari, M. et al. Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients. Transfusion Medicine 24, 227-232 (2014).
261. Khani, M. &Vakili, M. M. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Archives of Iranian Medicine 6, 1-4 (2003).
262. Khorvash, F., Fasihi Dastjerdi, M. &Emami Naeini, A. In 1st National Congress of Infection in Addicts. 23-29.
263. Khosravi, A., Bahmani, M. &Ghezel-Sofla, I. Co-infection by hepatitis C virus in human immunodeficiency virus infected patients in southwest of Iran. Iranian Journal of Clinical Infectious Diseases 5, 223-227 (2010).
264. Davoudi-kiakalayeh, A. Blood safety among beta-thalassemia major patients: Ten year experience in northern Iran. Vox Sanguinis 107, 152-153 (2014).
265. Lak, M., Peyvandi, F. &Mannucci, P. M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology 111, 1236-1239 (2000).
266. Langarodi, K. &Poorheravi, H. Prevalence of HCV among thalassemia patients in Shahid Bahonar hospital, Karaj. The Scientific Journal of Iranian Blood Transfusion Organization 8, 137-142 (2011).
267. Mahdaviani, F., Saremi, S. &Rafiei, M. Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004. The Scientific Journal of Iranian Blood Transfusion Organization 4, 313-322 (2008).
268. Mahdavimazdeh, M., Hosseini-Moghaddam, S. M., Alavian, S. M. &Yahyazadeh, H. Hepatitis B infection in hemodialysis patients in Tehran province, Iran. Hepatitis Monthly 9, 206-210 (2009).
269. Mak, V., Mombaini, H., Mirmoemen, S., Latefi, S. &Borhanpour, K. A study on the prevalence anti-hepatitis C virus among the hemodialysis patients referred to Sina hospital of Ahwaz. Jundishapur Scientific Medical Journal, 1-5 (2001).
270. Makhlough, A., Jamshidi, M. &Mahdavi, M. R. Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran. Singapore Medical Journal 49, 921-923 (2008).
271. Mansour-Ghanaei, F. et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Medical Science Monitor 8, CR797-CR800 (2002).
272. Mansour-Ghanael, F. et al. Prevalence of hepatitis B and C infection in hemodialysis patients of Rasht (Center of Guilan Province, Northern part of Iran). Hepatitis Monthly 9, 45-49 (2009).
273. Taheri-Azbarmi, Z. et al. Prevalence of Transfusion Transmitted Infections among patients with Major Thalassemia in Guilan, the north province of Iran. Transfusion 49(10), 2258 (2009).
274. Mashayekhi, S. O. et al. Prevalence of blood transfusion induced hepatitis among patients with thalassemia in Tabriz. Hepatology International 5(1), 225 (2011).
275. Meydani, M., Farzaneh, S., Ajami, B. &Hasanzadeh, A. Seroprevalence of HTLV1, 2 virus among injection drug addicts in Isfahan, 2007-2008. Journal of Shahid Sadoughi University of Medical Sciences 17, 286-290 (2009).
276. Mirahmadizadeh, A., Kadivar, M., Hemmati, A. &Javadi, A. In International Conference on AIDS. 16.
277. Mirahmadizadeh, A. R., Majdzadeh, R., Mohammad, K. &Forouzanfar, M. H. Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iranian Red Crescent Medical Journal 11, 325-329 (2009).
278. Mirmomen, S. et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with betathalassemia in Iran: A multicenter study. Archives of Iranian Medicine 9, 319-323 (2006).
279. Mobini, G. et al. Prevalence of anti-HCV antibody and related risk factors among bleeding disorder patients in Yazd province of Iran. Journal of Shahrekord University of Medical Sciences 12, 36-42 (2010).
280. Mohammadi, M. et al. Survey of both Hepatitis B Virus (HBsAg) and Hepatitis C Virus (HCV-Ab) coinfection among HIV positive patients. Virology Journal 6 (2009).
281. Momen-Heravi, M., Afzali, H. &Moosavipanah, H. Prevalence of anti HIV, ANTIHCV and, HBSAG positive among injection drug users in kashan-Iran. Journal of Clinical Immunology 32, S248 (2012).
282. Mousavi, F. A. B. M. A-IFN treatment of hepatitis C in thalassemic patients. Pejouhandeh 7, 21-24 (2002).
283. Mousavian, S., Mansouri, F., Saraei, A., Sadeghei, A. &Merat, S. Seroprevalence of hepatitis C in hemophilia patients refering to Iran Hemophilia Society Center in Tehran. Govaresh 16, 169-174 (2011).
284. Naini, M. M., Derakhshan, F., Hourfar, H., Derakhshan, R. &Rajab, F. M. Analysis of the related factors in hepatitis C virus infection among hemophilic patients in Isfahan, Iran. Hepatitis Monthly 7, 59-662 (2007).
285. Najafi, N., Baba Mohammadei, F. &Azizi, S. Prevalence of chronic hepatitis C in patients with positive HCV-Ab thalassemia referring to Razi clinic of Ghaemshahr hospital in 1998 [Persian]. Journal of Mazandaran University of Medical Sciences 11, 38-43 (2001).
286. Rahimi-Movaghar, A., Razaghi, E. M., Sahimi-Izadian, E. &Amin-Esmaeili, M. HIV, hepatitis C virus, and hepatitis B virus coinfections among injecting drug users in Tehran, Iran. International Journal of Infectious Diseases 14, e28-e33 (2010).
287. Ramezani, A. et al. Frequency and associated factors of proteinuria in Iranian HIV-positive patients. International Journal of Infectious Diseases 12, 490-494 (2008).
288. Ramezani, A. et al. Frequency of isolated hepatitis B core antibody in HIV-hepatitis C virus co-infected individuals. Int J STD AIDS 20, 336-338 (2009).
289. Ramezani, A. et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV 26, 1122-1126 (2014).
290. Rostami, Z., Lessan Pezeshki, M., Solemani Najaf Abadi, A. &Einollahi, B. Health related quality of life in iranian hemodialysis patients with viral hepatitis: Changing epidemiology. Hepatitis Monthly 13 (2013).
291. RostamiJalilian, M., Omid Ghaemi, M. &Kassaeian, N. Relationship of Hepatitis B and C with Deep Vein Thrombosis in I.V Drug Abusers. Journal of Military Medicine 8, 78-81 (2006).
292. Sabour, B., Boroumand, P., Elah, Y., Ghanbari, M. &Zarrinfam, H. Prevalence and risk factors of hepatitis C infection in hemodialysis patients (Kermanshah, 1999-2000). Journal of Kerman University of Medical Sciences 7, 60-66 (2003).
293. Saleh, M., Mohammad, K., Saleh, A., Asghar, H. &Rasool, S. Prevalence of HIV, hepatitis B and C seropositivity in expired IV drug abusers in Hamedan. Scientific Journal of Forensic Medicine 16, 253-257 (2011).
294. Sali, S., Nikbin, M., Yadegarinia, D., Hesseinifar, M. &Shahmuradi, M. HIV and viral hepatitis (B,D,c) co-infection, genotyping, epidemiological profile in west of Tehran. Sexually Transmitted Infections 89 (2013).
295. Sammak, H., Qomi, H. &Bitarafan, M. Prevalence of hepatitis B, C and HIV in patients with major β thalassaemia in Qom, 2007. Qom University of Medical Sciences Journal 4, Pe17-Pe20, En13 (2010).
296. Samarbaf-Zadeh, A. R. et al. Prevalence of hepatitis G virus among hemodialysis and kidney transplant patients in Khuzestan Province, Iran. Jundishapur Journal of Microbiology 8, 1-5 (2015).
297. Samimi-Rad, K. &Shahbaz, B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia 13, 156-163 (2007).
298. Samimi-Rad, K. et al. Prevalence of hepatitis C by RT-PCR in patients with thalassemia and hemophilia in Isfahan province 2005 [Persian]. Infectious and Tropical Diseases of Iran 11, 33-39 (2006).
299. Samimi-Rad, K. &Hosseini, M. Hepatitis C virus infection and hcv genotypes of hemodialysis patients. Iranian Journal of Public Health 37, 146-152 (2008).
300. Sanei-Moghaddam, E., Savadkoohi, S. &Rakhshani, F. Prevalence of hepatitis B and C in patients with major Beta-thalassaemia referred to Ali-Asghar hospital In Zahedan, 2002. Blood Sci J Iran 1, 19-26 (2004).
301. Tavanaee, S. &Khaleghi, N. Epidemiological evaluation and some species in injection drug users that admitted in infectious department of Imam Reza hospital (2007-2009). Journal of Medical Council of Islamic Republic of Iran 30, 155-161 (2012).
302. SeyedAlinaghi, S. et al. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta medica Iranica 49, 252-257 (2011).
303. Seyrafian, S., Mobasherizadeh, S., Javadi, A., Akhzari, M. &Esfandiari, J. In Nephrology Dialysis Transplantation. 484-484 (Oxford University Press).
304. Javadzadeh, S., Attar, M., Yavari, M. &Savabieh, S. Study of the prevalence of hepatitis B,C and HIV infection in hemophilia and thalassemia populations of Yazd. The Scientific Journal of Iranian Blood Transfusion Organization 2, 315-322 (2006).
305. Sharif, M., Sherif, A. &Sayyah, M. Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian Journal of Sexually Transmitted Diseases 30, 28-30 (2009).
306. Sharifi-Mood, B. et al. Viral infection among patients with hemophilia in the Southeast of Iran. Journal of Medical Sciences 6, 225-228 (2006).
307. Sharifi-Mood, B., Eshghi, P., Sanei-Moghaddam, E. &Hashemi, M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Medical Journal 28, 1516-1519 (2007).
308. Vaziri, S. et al. Hepatitis D virus infection among HIV-HBV co-infected patients in Kermanshah, West of Iran. Hepatitis Monthly 8, 252-257 (2008).
309. Sofian, M. et al. Viral hepatitis and HIV infection among injection drug users in a central iranian city. Journal of Addiction Medicine 6, 292-296 (2012).
310. Somi, M. H., Ardalan, M. R., Sokhanvar, H., Farhang, S. &Pouri, A. Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study. Archives of Clinical Infectious Diseases 2 (2007).
311. Somi, M. H. et al. Risk factors of HCV seroconversion in hemodialysis patients in Tabriz, Iran. Hepatitis Monthly 14 (2014).
312. Taremi, M., Khoshbaten, M., Gachkar, L., Ehsani Ardakani, M. J. &Zali, M. R. Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Iran. BMC Infectious Diseases 5 (2005).
313. Tayeri, K., Kasaeian, N., Fadaei, N. &Ataei, B. The prevalence of hepatitis B, hepatitis C and associated risk factors in intravenous drug addicts (IVDA) with HIV in Isfahan. Journal of Isfahan Medical School 26, 273-278 (2008).
314. Taziki, O. &Espahbodi, F. Prevalence of hepatitis C virus infection in hemodialysis patients. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 19, 475-478 (2008).
315. Toosi, M. N. et al. Risk factors and seroprevalence of hepatitis B and C infections among hemodialysis patients in Tehran. Iranian Journal of Pathology 2, 181-186 (2007).
316. Torabi, S. et al. Prevalence of hepatitis B and C in thalassemic patients of East Azarbaijan in 2003. The Scientific Journal of Iranian Blood Transfusion Organization 2, 115-122 (2005).
317. Torabi, S. et al. Prevalence of hepatitis B, C and HIV in hemophiliac patients of East Azarbaijan in 2004. The Scientific Journal of Iranian Blood Transfusion Organization 2, 291-299 (2006).
318. Valizadeh, N. et al. Seroprevalence of hepatitis C, hepatitis B and HIV viruses in hemophiliacs born 1985-2010 in west Azarbaijan of Iran. Asian J Transfus Sci 7, 55-58 (2013).
319. Yazdani, M. R., Kassaian, N., Ataei, B., Nokhodian, Z. &Adibi, P. Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. International Journal of Preventive Medicine 3 (2012).
320. Aminzadeh, Z. &Korough, S. Seroepidemiology of HIV, hepatitis B, hepatitis C and syphillis among injection drug addicts admitted to Loghman Hakim hospital, Tehran [Persian]. Journal of Medical Microbiology 1, 53-56 (2007).
321. Zahedi, M. J. &Darvishmoghadam, S. Frequency of Hepatitis B and C infection among Hemophiliac patients in Kerman. Journal of Kerman University of Medical Sciences 11, 131-135 (2004).
322. Zahedi, M. J., Moghaddam, S. D., Alavian, S. M. &Dalili, M. Seroprevalence of hepatitis viruses B, C, D and HIV infection among hemodialysis patients in Kerman province, South-East Iran. Hepatitis Monthly 12, 339-343 (2012).
323. Zali, M.-R., Aghazadeh, R., Nowroozi, A. &Amir-Rasouly, H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iran Med 4, 115-119 (2001).
324. Ziaee, M., Power, M., Hosseini, S. &Azarkar, G. Evaluation of hepatitis C infection and its prevalence in hemophilic patients in Khorasan [Persian]. Horizon of Knowledge 11, 54-60 (2005).
325. Ziaee, M., Zarban, A., Malekinejad, P. &Akhbary, H. Evaluation of HGV viremia prevalence and its co-infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran. Hepat Mon 7, 11-14 (2007).
326. Ziaee, M., Namaei, M. H. &Azarkar, G. The prevalence of HTLV-1 and its co-infection with HCV, HBV and HIV in hemophilic patients. Pakistan Journal of Medical Sciences 31, 1246-1249 (2015).